Pharmacological Treatments against COVID-19 in Pregnant Women
Abstract
:1. Introduction
2. Materials and Methods
3. Results
AUTHOR | YEAR | ARTICLE | TYPE OF ARTICLE | OBJECTIVES | RESULTS |
---|---|---|---|---|---|
Favilli et al. [12] | 2020 | Effectiveness and safety of available treatments for COVID-19 during pregnancy: a critical review. | Critical review | To provide a review of the literature on the presumed effectiveness and safety of available treatments for COVID-19 in pregnant women. | Pregnant women represent a fragile category of patients, generally excluded from trials, and the choice to use a COVID-19-specific drug must take into account the benefits and potential adverse events in each case. |
Malhamé et al. [11] | 2020 | The Moral Imperative to Include Pregnant Women in Clinical Trials of Interventions for COVID-19. | Literature review | Argue for the importance of including pregnant people in clinical trials of interventions for COVID-19. | The exclusion of pregnant women from clinical trials reduces the external validity of the study results. |
Louchet et al. [6] | 2020 | Placental transfer and safety in pregnancy of medications under investigation to treat coronavirus disease 2019. | Literature review | Analyse a number of drugs that may be compatible with pregnant women who have COVID-19. | Several drugs can now be used to treat pregnant women, but more pre-clinical studies are needed. |
Safaee et al. [18] | 2020 | High Concentrations of Nitric Oxide Inhalation Therapy in Pregnant Patients With Severe Coronavirus Disease 2019 (COVID-19). | Case studies | To test the efficacy of nitric oxide in pregnant patients with COVID-19 and respiratory failure. | Nitric oxide at 160–200 ppm is easy to use and well tolerated and therefore could be beneficial in pregnant COVID-19 patients with hypoxic respiratory failure. |
Liang et al. [8] | 2020 | Novel coronavirus disease (COVID-19) in pregnancy: What clinical recommendations to follow? | Literature review | To provide appropriate clinical management and support to pregnant patients, adopting a multidisciplinary team approach. | Pregnancy is a state of partial immunosuppression that makes pregnant women more vulnerable to viral infections. |
Cavalcante et al. [2] | 2021 | COVID-19 Treatment: Drug Safety Prior to Conception and during Pregnancy and Breastfeeding. | Literature review | To assess the state of the current literature on the safety of therapies prescribed to treat COVID-19 during pregnancy. | There is currently no specific effective treatment for COVID-19, but a large number of drugs are being used to combat SARS-CoV-2 infection. |
Taylor et al. [21] | 2021 | Inclusion of pregnant women in COVID-19 treatment trials: a review and global call to action. | Literature review | Provide pregnant women with information on the potential benefits and risks of exposure to candidate drugs for COVID-19 treatment. | The inclusion of pregnant women in clinical treatment trials is urgently needed to identify an effective COVID-19 treatment for this population. |
Lat et al. [15] | 2020 | Therapeutic options in the treatment of severe acute respiratory syndrome coronavirus 2 in pregnant patients. | Literature review | To provide a review of available treatments for COVID-19 in pregnant women. | There are few case studies of SARS-CoV-2 therapies in pregnant patients, so the initiation of any drug therapy should be a comprehensive, multidisciplinary risk-benefit discussion. |
Giampreti et al. [22] | 2020 | Medications prescriptions in COVID-19 pregnant and lactating women: The Bergamo Teratology Information Service experience during COVID-19 outbreak in Italy. | Case studies | To evaluate the efficacy and safety in pregnant women of various drugs for SARS-CoV-2 infection. | It should be noted that the safety of medicines during pregnancy is a constantly changing issue. |
Bardon et al. [20] | 2020 | How should we treat pregnant women infected with SARS-CoV-2? | Literature review | Raise public awareness of the importance of not excluding pregnant women with COVID-19 from studies. | Pregnant women are as exposed as the general population and should not be excluded from discussions on effective and well-tolerated candidate treatments because of their status. |
Saad et al. [16] | 2020 | Corticosteroids in the Management of Pregnant Patients With Coronavirus Disease (COVID-19). | Literature review | Assess possible initiation of maternal corticosteroid therapy and possible side effects. | Pregnant women with COVID-19 who require oxygen therapy or mechanical ventilation, or both, should be considered for steroid therapy. |
Lai et al. [10] | 2020 | Severe acute respiratory syndrome coronavirus-2 and the deduction effect of angiotensin-convertingenzyme 2 in pregnancy. | Literature review | To analyse a case series of pregnant women with COVID-19. | SARS-CoV-2 is an ongoing disease, and the experience of pregnant women with SARS-CoV-2 is limited. |
Mcintosh [17] | 2020 | Corticosteroid Guidance for Pregnancy during COVID-19 Pandemic. | Literature review | To examine the risks and benefits of corticosteroid therapy in pregnant women with COVID-19. | There is limited evidence on corticosteroid treatment in pregnant women with COVID-19. Therefore, a careful assessment of maternal risk versus neonatal benefit should be made. |
Thomas et al. [7] | 2020 | Maternal and perinatal outcomes and pharmacological management of COVID-19 infection in pregnancy: A systematic review protocol. | Systematic review | To summarise the existing data on the effects of COVID-19 in the maternal population, address the therapeutic management and safety of drugs to treat COVID-19 during pregnancy and lactation. | There is a paucity of information related to pharmacological management and maternal and perinatal outcomes during the pandemic. |
D’Souza et al. [4] | 2021 | Pregnancy and COVID-19: pharmacologic considerations. | Literature review | To summarise the evidence regarding the use of routine and investigational pharmacological interventions for pregnant patients with COVID-19. | The vast majority of common antepartum pharmacological interventions can be used in women with COVID-19. |
Li et al. [23] | 2020 | Antiviral agent therapy optimization in special populations of COVID-19 patients. | Literature review | Review articles that focus on antiviral agents in patients with COVID-19 and summarise possible antiviral options against COVID-19. | Individual antiviral treatment should be carried out to achieve better clinical outcomes and to avoid adverse drug reactions. |
Lambelet et al. [3] | 2020 | SARS-CoV-2 in the context of past coronaviruses epidemics: Consideration for prenatal care. | Literature review | To describe the current knowledge on the risks and consequences of COVID-19 in pregnancies, to summarise the current treatment options available to pregnant women, and finally, to compare the current guidance proposed by RCOG, ACOG and WHO to provide an overview of the prenatal management that should be used until future data become available. | More comprehensive data are needed to understand the additional risks that pregnancy may pose to women with COVID-19 infection. |
Whitehead et al. [9] | 2020 | Consider pregnancy in COVID-19 therapeutic drug and vaccine trials. | Literature review | To analyse a case series of pregnant women with COVID-19. | The COVID-19 pandemic highlights the vulnerability of sick pregnant women if they are systematically excluded from clinical trials. |
Zhao et al. [24] | 2020 | Analysis of the susceptibility to COVID-19 in pregnancy and recommendations on potential drug screening. | Bibliographic review | To analyse the susceptibility of SARS-CoV-2 in pregnancy and the drugs that can be used to treat pregnancy with COVID-19 and to provide evidence for drug selection in the clinic. | Large-scale investment is needed in research and development of vaccines and therapeutic drugs against coronavirus, in which pregnant women are a group that cannot be excluded. |
Castro et al. [19] | 2020 | COVID-19 and Pregnancy: An Overview. | Literature review | Provide a brief discussion of COVID-19, pregnancy in the COVID-19 era and the effects of COVID-19 on pregnancy. | With the onset of the pandemic, research should be conducted on the effects of viraemia during the first and second trimester and the prediction of possible adverse outcomes. |
Afshar et al. [5] | 2020 | Clinical guidance and perinatal care in the era of coronavirus disease 2019 (COVID-19). | Literature review | To review a case series of pregnant women with COVID-19. | At this time, there remain significant gaps in the evidence to enable comprehensive counselling of pregnant women and their families, specifically with respect to outcome risks. |
Peyronnet et al. [1] | 2020 | Infection with SARS-CoV-2 in pregnancy. Update of Information and proposed care. CNGOF. | Literature review | To analyse a case series of pregnant women with COVID-19. | There is a need to continue to collect data on clinical cases of SARS-CoV-2 infection during pregnancy and to improve our understanding of the course of the disease during pregnancy. |
4. Discussion
Limitations
5. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Peyronnet, V.; Sibiude, J.; Huissoud, C.; Lescure, F.X.; Lucet, J.C.; Mandelbrot, L.; Nisan, I.; Belaish-Allart, J.; Vayssiere, C.; Yazpandanah, Y.; et al. Infection with SARS-CoV-2 in preg-nancy. Update of Information and proposed care. CNGOF 2020, 48, 858–870. [Google Scholar]
- Cavalcante, M.B.; Cavalcante, C.T.D.M.B.; Braga, A.C.S.; Andrade, D.A.; Montenegro, M.A.; Santos, P.A.N.; Motoyama, P.V.P.; Rocha, M.G.; Dib, L.A.; Júnior, E.A. COVID-19 Treatment: Drug Safety Prior to Conception and During Pregnancy and Breastfeeding. Geburtshilfe Frauenheilkd. 2021, 81, 46–60. [Google Scholar] [PubMed]
- Lambelet, V.; Vouga, M.; Pomar, L.; Favre, G.; Gerbier, E.; Panchaud, A.; Baud, D. SARS-CoV-2 in the context of past coronaviruses epidemics: Consideration for prenatal care. Prenat Diagn. 2020, 40, 1641–1654. [Google Scholar] [CrossRef]
- D’Souza, R.; Ashraf, R.; Rowe, H.; Zipursky, J.; Clarfield, L.; Maxwell, C.; Arzola, C.; Lapinsky, S.; Paquette, K.; Murhy, S.; et al. Pregnancy and COVID-19: Pharmacologic consider-ations. Ultrasound Obstet. Gynecol. 2021, 57, 195–203. [Google Scholar] [CrossRef]
- Afshar, Y.; Silverman, N.S.; Han, C.S.; Platt, L.D. Clinical guidance and perinatal care in the era of coronavirus disease 2019 (COVID-19). J. Peérinat. Med. 2020, 48, 925–930. [Google Scholar] [CrossRef] [PubMed]
- Louchet, M.; Sibiude, J.; Peytavin, G.; Picone, O.; Tréluyer, J.M.; Mandelbrot, L. Placental transfer and safety in pregnancy of medications under investigation to treat coronavirus disease. Am. J. Obstet. Gynecol. 2020, 2, 100–159. [Google Scholar]
- Thomas, B.; Pallivalapila, A.; Elkassem, W.; Tarannum, A.; Al Hail, F.; Rijims, M.; Parappil, H.; Bayo, A.I.; Ahmad, S.; Nazar, Z.; et al. Maternal and perinatal outcomes and pharmacological management of Covid-19 infection in pregnancy: A systematic review protocol. Syst. Rev. 2020, 9, 1–7. [Google Scholar] [CrossRef]
- Liang, H.; Acharya, G. Novel corona virus disease (COVID-19) in pregnancy: What clinical recommendations to follow? Acta Obstet. Gynecol. Scand. 2020, 99, 439–442. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Whitehead, C.L.; Walker, S.P. Consider pregnancy in COVID-19 therapeutic drug and vaccine trials. Lancet 2020, 395, e92. [Google Scholar] [CrossRef]
- Lai, Y.-J.; Chang, C.-M.; Lina, C.-K.; Yang, Y.-P.; Chien, C.-S.; Wang, P.-H.; Changa, C.-C. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and the deduction effect of angiotensin-converting enzyme 2 (ACE2) in pregnancy. J. Chin. Med Assoc. 2020, 83, 812–816. [Google Scholar] [CrossRef]
- Favilli, A.; Gentili, M.M.; Raspa, F.; Giardina, I.; Parazzini, F.; Vitagliano, A.; Borisova, A.V.; Gerli, S. Effectiveness and safety of available treatments for COVID-19 during pregnancy: A critical review. J. Matern. Neonatal. Med. 2020, 1–14. [Google Scholar] [CrossRef]
- Malhamé, I.; D’Souza, R.; Cheng, M.M.P. The Moral Imperative to Include Pregnant Women in Clinical Trials of Interventions for COVID-19. Ann. Intern. Med. 2020, 173, 836–837. [Google Scholar] [CrossRef] [PubMed]
- Verhagen, A.P.; De Vet, H.C.; De Bie, R.A.; Kessels, A.G.; Boers, M.; Bouter, L.M.; Knipschild, P.G. The Delphi list: A criteria list for quality assessment of randomised clinical trials for conducting systematic reviews developed by Delphi consensus. J. Clin. Epidemiol. 1998, 51, 1235–1241. [Google Scholar] [CrossRef] [Green Version]
- AMSTAR-2: Critical appraisal tool for systematic reviews of healthcare interventions. EVIDENCE 2021, 21, 1–8. Available online: www.evidencia.org.ar (accessed on 3 March 2021). [CrossRef]
- Lat, T.I.; Patel, C.D.; Ehrig, J.C.; Moslander, C.; Sanchez, J.F. Therapeutic options in the treatment of severe acute respiratory syndrome coronavirus 2 in pregnant patient. Am. J. Obstet. Gynecol. MFM 2020, 2, 100224. [Google Scholar] [CrossRef]
- Saad, A.F.; Chappell, L.; Saade, G.R.; Pacheco, L.D. Corticosteroids in the Management of Pregnant Patients with Coronavirus Disease (COVID-19). Obstet. Gynecol. 2020, 136, 823–826. [Google Scholar] [CrossRef] [PubMed]
- McIntosh, J. Corticosteroid Guidance for Pregnancy during COVID-19 Pandemic. Am. J. Perinatol. 2020, 37, 809–812. [Google Scholar] [CrossRef] [Green Version]
- Fakhr, B.S.; Wiegand, S.B.; Pinciroli, R.; Gianni, S.; Morais, C.C.A.; Ikeda, T.; Miyazaky, Y.; Muratani, E.; Di Fenza, R.; Larson, G.M.; et al. High Concentrations of Nitric Oxide Inhalation Therapy in Pregnant Patients with Severe Coronavirus Disease 2019 [COVID-19]. Obstet Gynecol. 2020, 136, 1109–1113. [Google Scholar] [CrossRef] [PubMed]
- Castro, P.; Matos, A.P.; Werner, H.; Lopes, F.P.; Tonni, G.; Júnior, E.A. Covid-19 and Pregnancy: An Overview. Revista Brasileira de Ginecologia e Obstetrícia/RBGO Gynecol. and Obstetrics 2020, 42, 420–426. [Google Scholar] [CrossRef] [PubMed]
- Faure-Bardon, V.; Salomon, L.J.; Leruez-Ville, M.; Ville, Y. How should we treat pregnant women infected with SARS-CoV-2? Int. J. Obstet. Gynaecol. 2020, 127, 1050–1052. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Taylor, M.M.; Kobeissi, L.; Kim, C.; Amin, A.; Thorson, A.E.; Bellare, N.B.; Brizuela, V.; Bonet, M.; Kara, E.; Thwin, S.S.; et al. Inclusion of pregnant women in COVID-19 treatment trials: A review and global call to action. Lancet Glob. Health 2021, 9, e366–e371. [Google Scholar] [CrossRef]
- Giampreti, A.; Eleftheriou, G.; Gallo, M.; Butera, R.; Contessa, G.; Faraoni, L.; Sangiovanni, A.; Negri, G.; Falchi, G.; Bacis, G. Medications prescriptions in COVID-19 pregnant and lactating women: The Bergamo Teratology Information Service experience during COVID-19 outbreak in Italy. J. Peérinat. Med. 2020, 48, 1001–1007. [Google Scholar] [CrossRef] [PubMed]
- Li, L.; Wang, X.; Wang, R.; Hu, Y.; Jiang, S.; Lu, X. Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients. Drug Des. Dev. Ther. 2020, 14, 3001–3013. [Google Scholar] [CrossRef] [PubMed]
- Zhao, X.; Jiang, Y.; Zhao, Y.; Xi, H.; Liu, C.; Qu, F.; Feng, X. Analysis of the susceptibility to COVID-19 in pregnancy and recommendations on potential drug screening. Eur. J. Clin. Microbiol. Infect. Dis. 2020, 39, 1209–1220. [Google Scholar] [CrossRef] [PubMed]
- Danza, Á.; Graña, D.; Goñi, M.; Vargas, A.; Ruiz-Irastorza, G. Hidroxicloroquina en el tratamiento de las enfermedades autoinmunes sistémicas. Rev. Med. Chile 2016, 144, 232–240. Available online: http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872016000200012&lng=es (accessed on 3 March 2021). [CrossRef] [PubMed] [Green Version]
Drug | FDA Category |
---|---|
Anticoagulants | B |
Corticosteroids | C, D |
Convalescent or hyperimmune plasma | No data |
Remdesivir | B |
Chloroquine/hydroxychloroquine | C |
Lopinavir/ritonavir | C |
Azithromycin | B |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Arco-Torres, A.; Cortés-Martín, J.; Tovar-Gálvez, M.I.; Montiel-Troya, M.; Riquelme-Gallego, B.; Rodríguez-Blanque, R. Pharmacological Treatments against COVID-19 in Pregnant Women. J. Clin. Med. 2021, 10, 4896. https://doi.org/10.3390/jcm10214896
Arco-Torres A, Cortés-Martín J, Tovar-Gálvez MI, Montiel-Troya M, Riquelme-Gallego B, Rodríguez-Blanque R. Pharmacological Treatments against COVID-19 in Pregnant Women. Journal of Clinical Medicine. 2021; 10(21):4896. https://doi.org/10.3390/jcm10214896
Chicago/Turabian StyleArco-Torres, Ana, Jonathan Cortés-Martín, María Isabel Tovar-Gálvez, María Montiel-Troya, Blanca Riquelme-Gallego, and Raquel Rodríguez-Blanque. 2021. "Pharmacological Treatments against COVID-19 in Pregnant Women" Journal of Clinical Medicine 10, no. 21: 4896. https://doi.org/10.3390/jcm10214896